ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Varmus: Why are scientific societies obstructing public access to research results?

May 20, 2005

Randomized Low-Fat Diet Trial To Being, Centers Sought

September 17, 1993

PET Tracer Drug Approved, Developed At Weill Cornell

September 24, 2004

In Brief: Cox Leaving Columbia To Be Physician In Chief At M.D. Anderson; Will Continue to Head RTOG

April 15, 1988

“NCI activities at Frederick are not well integrated…. It would be wise to reorganize and consolidate.”

July 21, 1995

ASCO, NCCN Develop Quality Measures For Cancer Care

August 25, 2006